Erratum: ACE2 inhibition worsens glomerular injury associated with increased ACE expression in streptozotocin-induced diabetic mice (Kidney International (2007) 72, (614-623) DOI: 10.1038/sj.ki.5002373);ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice

Kidney International

Volumn 72, Issue 5, 2007, Pages 614-623

  Soler, M J ^a   Wysocki, J ^a   Ye, M ^a   Lloveras, J ^b   Kanwar, Y ^a   Batlle, D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

ACE; ACE2; ACE2 inhibition; Albuminuria; Diabetic nephropathy; Renal histology

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN II ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MLN 4760; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEGRADATION; EPITHELIUM CELL; FEMALE; GLOMERULAR STRUCTURE; GLOMERULONEPHRITIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES;

EID: 34548153521     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002539     Document Type: Erratum

References (48)

1. Crackower MA, Sarao R, Oudit GY et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-828.
2. Donoghue M, Hsieh F, Baronas E et al. A novel angiotensin- converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-E9.
3. Tipnis SR, Hooper NM, Hyde R et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275: 33238-33243.
4. Li N, Zimpelmann J, Cheng K et al. The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by rat proximal tubules. Am J Physiol Renal Physiol 2005; 288: F353-F362.
5. Eriksson U, Danilczyk U, Penninger JM. Just the beginning: novel functions for angiotensin-converting enzymes. Curr Biol 2002; 12: R745-R752.
6. Ye M, Wysocki J, Naaz P et al. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 2004; 43: 1120-1125.
7. Ye M, Wysocki J, William J et al. Glomerular localization and expression of angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 2006; 17: 3067-3075.
8. Oudit GY, Herzenberg AM, Kassiri Z et al. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 2006; 168: 1808-1820.
9. Imai Y, Kuba K, Rao S et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436: 112-116.
10. Gurley SB, Allred A, Le TH et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 2006; 116: 2218-2225.
11. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000; 57: 1803-1817.
12. Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 2003; 14: 274-281.
13. Hollenberg NK, Raij L. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. Arch Intern Med 1993; 153: 2426-2435.
14. Tikellis C, Johnston CI, Forbes JM et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003; 41: 392-397.
15. Wysocki J, Ye M, Soler MJ et al. ACE and ACE2 activity in diabetic mice. Diabetes 2006; 55: 2132-2139.
16. Turoni CM, Reynoso HA, Maranon RO et al. Structural changes in the renal vasculature in streptozotocin-induced diabetic rats without hypertension. Nephron Physiol 2005; 99: p50-p57.
17. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996; 27: 523-528.
18. Oliveira MA, Fortes ZB, Santos RA et al. Synergistic effect of angiotensin-(1-7) on bradykinin arteriolar dilation in vivo. Peptides 1999; 20: 1195-1201.
19. Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999; 33: 207-211.
20. Wolf G, Mueller E, Stahl RA et al. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993; 92: 1366-1372.
21. Wolf G, Neilson EG. Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells. Am J Physiol 1990; 259: F768-777.
22. Su Z, Zimpelmann J, Burns KD. Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 2006; 69: 2212-2218.
23. Wang LJ, He JG, Ma H et al. Chronic administration of angiotensin-(1-7) attenuates pressure-overload left ventricular hypertrophy and fibrosis in rats. Di Yi Jun Yi Da Xue Xue Bao 2005; 25: 481-487.
24. Esther Jr CR, Howard TE, Marino EM et al. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 1996; 74: 953-965.
25. Sequeira Lopez ML, Gomez RA. The role of angiotensin II in kidney embryogenesis and kidney abnormalities. Curr Opin Nephrol Hypertens 2004; 13: 117-122.
26. Huang W, Gallois Y, Bouby N et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci USA 2001; 98: 13330-13334.
27. Vickers C, Hales P, Kaushik V et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277: 14838-14843.
28. Singh R, Singh AK, Alavi N et al. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 2003; 14: 873-880.
29. Camargo de Andrade MC, Di Marco GS, de Paulo Castro Teixeira V et al. Expression and localization of N-domain ANG I-converting enzymes in mesangial cells in culture from spontaneously hypertensive rats. Am J Physiol Renal Physiol 2006; 290: F364-375.
30. Sadjadi J, Kramer GL, Yu CH et al. Angiotensin II exerts positive feedback on the intrarenal renin-angiotensin system by an angiotensin converting enzyme-dependent mechanism. J Surg Res 2005; 129: 272-277.
31. Metsarinne KP, Helin KH, Saijonmaa O et al. Tissue-specific regulation of angiotensin-converting enzyme by angiotensin II and losartan in the rat. Blood Press 1996; 5: 363-370.
32. Sugiyama T, Yoshimoto T, Tsuchiya K et al. Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Endocrinology 2005; 146: 3900-3906.
33. Saijonmaa O, Nyman T, Kosonen R et al. Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. Am J Physiol Heart Circ Physiol 2001; 280: H885-H891.
34. Cohen MP, Chen S, Ziyadeh FN et al. Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy. Kidney Int 2005; 68: 1554-1561.
35. Kakizawa H, Itoh Y, Imamura S et al. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist. Horm Metab Res 2004; 36: 458-464.
36. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265: F477-F486.
37. Ingelfinger JR. ACE2: a new target for prevention of diabetic nephropathy? J Am Soc Nephrol 2006; 17: 2957-2959.
38. Nakagawa T, Mazzali M, Kang DH et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003; 23: 2-7.
39. Dai C, Yang J, Bastacky S et al. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. J Am Soc Nephrol 2004; 15: 2637-2647.
40. Susztak K, Bottinger E, Novetsky A et al. Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes 2004; 53: 784-794.
41. Isbel NM, Nikolic-Paterson DJ, Hill PA et al. Local macrophage proliferation correlates with increased renal M-CSF expression in human glomerulonephritis. Nephrol Dial Transplant 2001; 16: 1638-1647.
42. Metzger R, Bohle RM, Pauls K et al. Angiotensin-converting enzyme in non-neoplastic kidney diseases. Kidney Int 1999; 56: 1442-1454.
43. Kaneto H, Morrissey J, Klahr S. Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 1993; 44: 313-321.
44. Miyazaki Y, Tsuchida S, Fogo A et al. The renal lesions that develop in neonatal mice during angiotensin inhibition mimic obstructive nephropathy. Kidney Int 1999; 55: 1683-1695.
45. Sung SH, Ziyadeh FN, Wang A et al. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006; 17: 3093-3104.
46. Kasahara Y, Ashihara Y. Colorimetry of angiotensin-I converting enzyme activity in serum. Clin Chem 1981; 27: 1922-1925.
47. Takemoto M, Asker N, Gerhardt H et al. A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 2002; 161: 799-805.
48. Volland H, Pradelles P, Ronco P et al. A solid-phase immobilized epitope immunoassay (SPIE-IA) permitting very sensitive and specific measurement of angiotensin II in plasma. J Immunol Methods 1999; 228: 37-47.